[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-361080-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-361080-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","epigenetic-silencing-of-mir-141-via-core-promoter-methylation-is-associated-with-short-term-bladder-cancer-progression-research-paper","Epigenetic silencing of miR-141 via core promoter methylation is associated with short-term bladder cancer progression - research paper","","Epigenetic alterations in DNA methylation are examined for their role in bladder tumorigenesis and clinical outcomes. The study maps the DNA methylation landscape of the MIR141 promoter and links it to bladder cancer relevance. miRNA-seq defines miR-141-3p downregulation, while expression and promoter methylation are assessed in patient-derived xenografts and a screening cohort. TCGA-BLCA validates the findings. MIR141 core promoter hypermethylation correlates with advanced grade, reduced survival, and short-term progression risk, supporting improved prognostication beyond traditional markers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/epigenetic-silencing-of-mir-141-via-core-promoter-methylation-is-associated-with-short-term-bladder-cancer-progression-research-paper/361080/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/epigenetic-silencing-of-mir-141-via-core-promoter-methylation-is-associated-with-short-term-bladder-cancer-progression-research-paper/361080.png","ImageObject",300,407,{"name":42,"@type":43},"awa","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What molecular mechanism links miR-141 silencing to bladder cancer progression?","Question",{"text":63,"@type":64},"The study links miR-141-3p loss to hypermethylation of the MIR141 core promoter, indicating epigenetic silencing as a driver associated with progression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was miR-141 regulation measured across bladder cancer samples?",{"text":68,"@type":64},"miRNA-seq was used to characterize miRNA profiles, alongside expression analysis of miR-141-3p and methylation profiling of the MIR141 promoter in patient-derived xenografts and a screening patient cohort.",{"name":70,"@type":61,"acceptedAnswer":71},"Which patient outcomes did MIR141 promoter methylation predict?",{"text":72,"@type":64},"MIR141 core promoter hypermethylation was associated with advanced stage and high-grade tumors, reduced survival in PDX models, and a significantly higher risk of short-term progression in non-muscle-invasive TaT1 patients.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},361080,1790167209,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Epigenetic silencing of miR-141 via core promoter methylation is associated with short-term bladder cancer progression  \nReceived for publication, January 14, 2026, and in revised form, June 19, 2026 Published, Papers in Press, June 29, 2026 [https://doi.org/10.1016/j.jbc.2026.1](https://doi.org/10.1016/j.jbc.2026.1)13302  \nKaterina-Marina Pilala 1, Artemis-Melina Papadimitriou 1, Maria-Alexandra Papadimitriou 1,  \nKonstantina Panoutsopoulou 1, Georgios-Christos Giagkos2, Panagiotis Levis2, Zoi Kanaki3,  \nDido Vassilacopoulou 1, Konstantinos Stravodimos2, Apostolos Klinakis3, Andreas Scorilas 1, and  \nMargaritis Avgeris 1,4,*  \nFrom the 1Department of Biochemistry and Molecular Biology, Faculty of Biology, National and Kapodistrian University of Athens, Athens, Greece; 2First Department of Urology, \"Laiko\" General Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; 3Biomedical Research Foundation Academy of Athens, Athens, Greece; 4Laboratory of Clinical Biochemistry-Molecular Diagnostics, Second Department of Pediatrics,”P. & A. Kyriakou“ Children’s Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece  \nReviewed by members of the JBC Editorial Board. Edited by Brian D. Strahl  \nAlterations in DNA methylation represent one of the earliest molecular events in bladder tumorigenesis and are strongly associated with treatment efficacy and prognosis. Herein, we investigated DNA methylation landscape of MIR141 promoter and elucidated its clinical relevance in bladder cancer (BlCa) patients. miRNA-seq was performed to analyze miRNA profile in bladder tumors. Expression analysis of miR-141-3p and methylation profiling of MIR141 promoter were performed in 15 patient-derived xenografts (PDXs) mouse models, and in our screening patients’ cohort (n = 133). TCGA-BLCA (n = 412) was used as independent validation cohort. Survival analysis was performed employing tumor relapse/progression as clinical endpoints in non-muscleinvasive BlCa (NMIBC; TaT1), and mortality in muscleinvasive BlCa (MIBC; T2–T4) patients. Internal validation was conducted through bootstrap analysis, and the clinical benefit of the findings was evaluated using decision curve analysis. miRNA-seq highlighted miR-141-3p as one of the most significantly downregulated miRNAs in muscle-invasive and high-grade tumors, while PDXs, TCGA-BLCA and screening cohort revealed its robust epigenetic regulation through MIR141 core promoter methylation. Consistent with miR-141-3p loss, hypermethylation of MIR141 core promoter was associated with advanced stage and high-grade tumors, reduced survival in PDXs, and significantly higher risk of TaT1 patients for short-term progression to muscle-invasive disease. Multivariate models highlighted MIR141 promoter hypermethylation as independent predictor for NMIBC short-term progression, displaying superior clinical benefit in patients’prognostication. Overall, MIR141 core promoter methylation results in miR-141-3p loss in bladder tumors and correlates with patients’ poor treatment outcome, offering improved  \n* For correspondence: Dr Margaritis Avgeris, [margaritis.avgeris@gmail.com](margaritis.avgeris@gmail.com), [mavgeris@med.uoa.gr](mavgeris@med.uoa.gr).  \nrisk-stratification and addressing prognostic heterogeneity beyond traditional markers.  \nBladder cancer (BlCa) stands as the sixth most common cancer and the ninth leading cause of cancer-related death among men globally, with Europe displaying the highest incidence (fourth) and mortality (sixth) rates (1, 2). The most prevalent histological disease subtype is the urothelial bladder carcinoma (UBC; >90%), arising from the urothelial lining of the bladder (3). Depending on the extent of invasion into the detrusor muscle, BlCa is classified into two major groups: non-muscle-invasive bladder cancer (NMIBC; Tis, Ta and T1), where the tumor remains confined to the mucosa or submucosa, and muscle-invasive bladder c","cbCaijRQyErVzUUO","https://ap.wps.com/l/cbCaijRQyErVzUUO","pdf",5701237,13,"English","# Introduction\n# Methods and cohorts\n## miRNA-seq and methylation profiling\n## Validation and survival/clinical benefit analyses\n# Results and clinical significance\n# Conclusion and implications","[{\"question\":\"What molecular mechanism links miR-141 silencing to bladder cancer progression?\",\"answer\":\"The study links miR-141-3p loss to hypermethylation of the MIR141 core promoter, indicating epigenetic silencing as a driver associated with progression.\"},{\"question\":\"How was miR-141 regulation measured across bladder cancer samples?\",\"answer\":\"miRNA-seq was used to characterize miRNA profiles, alongside expression analysis of miR-141-3p and methylation profiling of the MIR141 promoter in patient-derived xenografts and a screening patient cohort.\"},{\"question\":\"Which patient outcomes did MIR141 promoter methylation predict?\",\"answer\":\"MIR141 core promoter hypermethylation was associated with advanced stage and high-grade tumors, reduced survival in PDX models, and a significantly higher risk of short-term progression in non-muscle-invasive TaT1 patients.\"}]","Epigenetic silencing of miR-141 via core promoter methylation is associated with short-term bladder cancer progression - research paper | PDF",1790143052,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5088106932d693c6ee3356a9e227d91.webp",983,1296,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/40fee3cea03083a86e87e2bb71f836ee.webp",982,1294,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8eb5a47f109b65152dde6bf7a5c54dd.webp",981,1293,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da0b7ad3239246983a50f517e6539698.webp",980,1292]